Xenon Pharmaceuticals (XENE) – Company Press Releases
-
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
-
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
-
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
-
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
-
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
-
Xenon Pharmaceuticals Announces Proposed Public Offering
-
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
-
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
-
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
-
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
-
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
-
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
-
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
-
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
-
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
-
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
-
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
-
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
-
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
-
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
-
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
Back to XENE Stock Lookup
